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Abstract: Resistance to intestinal proteases and efficacy against verotoxin (VT) 2 of a colostral antibody
administered orally via catheter were investigated in beagle dogs. Bovine colostral antibody remained in the
small intestine for 2 hours, whereas little serum antibody remained at 1.5 hours after administration. The
bovine colostral antibody was not inactivated by proteases in the small intestine. Furthermore, the antibody
activity of S-IgA did not change until 2 hours after administration; however, the activity of IgG and IgM
antibodies decreased by two-thirds and two-fifths at 2 hours after administration, respectively.
  Seven beagle dogs inoculated with lischerichia coli (E coli) O157:H7 producing VT2 were administered
bovine colostral antibody or bovine colostral whey without antibody. With administration of bovine colostral
whey without antibody, the amount of VT2 in feces decreased gradually after administration and increased
again at 5 days after inoculation, while bovine colostral antibody significantly reduced the amount of VT2 in
feces the day after administration. In addition, 9 beagle dogs were administered bovine colostral antibody,
bovine plasma antibody or sali.ne. The amount of VT2 in feces also significantly reduced rapidly after
administration ofboyine colostral antibody than administration ofbovine plasma antibody or saline.
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                [ntroduction
  In Japan, a diffuse outbreak of enterohemorrhagic
Escherichia coli (EHEC) O157:H7 infection occurred
among schoolchildren in Sakai city, Osaka prefecture, in
July 1996.4･i8 In that year, numerous outbreaks of food
poisoning due to Escherichia coli O157:H7 occurred in
various localities throughout Japan, and such outbreaks
became a social problem.i8 Escherichia coli (E. coli)
O157:H7 infection is monitored in Japan, in accordance
with the Infection Diseases Control Law, and in 2005,
3,589 cases were reported.iO Furthermore, incidents of
EHEC infection occur in many industrialized nations.20
Thus, EHEC infection is an emergent infectious disease of
significant clinical importance.11, 12, 22
  The th rapeutic app oaches for EHEC infection are the
subject of widespread discussion.9･ 24･ 30 Generally, the
treatment for bacterial food poisoning is the
adm nistration of antibiotics; however, administration of
ntibiotic  is no  commended for food poisoning caused
by EHEC infection, as this increases the risk of serious
complications, such as hemolytic uremic syndrome
(HUS), due to verotoxin (VT) released from EHEC killed
by antibiotics. Appropriate therapeutic approaches, such
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as inhibiting VT activity or absorption from the intestine,
are thus required. The authors previously obtained a
bovine colostral antibody against VT2 from cows
immunized with VT2.i4 Furthermore, we confirmed the
neutralization efficacy of this bovine colostral antibody
against VT2 in mice.i4 However, if this bovine colostral
antibody is administered orally to patients infected with
E. coli O157, its resistance to decomposition by intestinal
proteases must be investigated. Although neutralization
efficacy against VT2 has been verified in mice, resistance
to proteases could not be confirmed. Moreover, many
studies of proteolytic degradation of immunoglobulin (Ig)
in vitro have been perfbrmed, and each Ig class reportedly
has different resistances to protease degradation.3, 2i, 25,26
However, Ig resistance to proteases has no! been clarified
in vivo. Furtheremore, few appropriate experimental
animals are able to evaluate for E coli O157:H7.infection.
The weaned immature mouse model was used for E coli
O157:H7 infection and VT(Iwakura et al. The 77th
Annual Meeting of the Japanese Association for infectious
Diseases. 2003. 238).i4 Nothing is model of beagle dogs
for E. coli O157:H7 infection. However, diarrhea was
shown in beagle dogs inoculated of E. coli O157:H7 by
pre-treatment of fradiomycin. Then, this model was used
in our study.
  In this study, the resistance of bovine colostral antibody
to proteases in the small intestine of beagle dogs, as well
as that of each Ig class isolated from intestinal fluid after
administration of bovine colostral antibody, was
investigated. Furthermore, efficacy against VT2 in beagle
dogs was also investigated.
            Materials and Methods
Microorganisms and VT2
  E. coli O157:H7 producing VT2 isolated from humans
was used in this study. E. coli O157:H7 was cultured
using brain heart infusion broth (Difeo, Becton, Dickinson
and Company, NJ, USA) for 48 hours, and culture
supematant was obtained by centrifugation (1,600 × g, 20
minutes). Microorganisms were suspended in sterile saline
and diluted to 1 × 109 CFUIml for administration to
beagle dogs.
  VT2 in culture med um and feces was measured using a
comm rcia  ki  (VTEC RLPA, DENKA SEIKEN Co.,
Ltd., Tokyo, Japan) based on reversed passive latex
agglutination.
Animal
  Nine beagle dogs aged 1 year (8 males and 1 female;
Saitama Experimental Animals Supply Co., Ltd., Saitama,
Japan) and twenty-three male beagle dogs aged 1 year
(AQS Co., Ltd., Chiba, Japan) were used. Four male
Japanese white rabbits were obtained from Saitama
Experi ental Animals Supply Co., Ltd. (Saitama, Japan),
and three 6- to 8-year-old dairy cows (3 to 4 months prior
to livery) bred at a cattle farm in Shimane prefecture,
Japan, were used.
  Dogs and rabbits were reared individually in cages
housed in an an mal r om maintained at a temperature of
22 ± 2eC and humidity of 60 ± 10% with a 12-h
Iightldark cycle (07:OO-19:OO), and the air was changed 15
timeslh. Dogs were fed solid stock food (Oriental Yeast
Co., Lt ., Tokyo, Japan) and were allowed free access to
water.
  All exper ments conformed to Japanese regulations
co ceming animal care and use, as specified in the
Guidelines for Animal Experimentation (Japanese
Association for Lab ratory Animal Science, JALAS,
1987), and were approved by the Animal Research
C m t ee of Azabu University.
Immunization to cows with VT2
  Two cows were immunized in order to obtain sufficient
bovine colostral antibody for the study. Immunization of
6-year-old cows with VT2 was as described by
Kuribayashi et al.i4 Eight-year-old cows were
intradermally im unized with the supernatant of culture
medium cont ining VT2 mixed with (1:1) Freund's
complete adjuvant (Difco Laboratories, Detroit, USA)
initially, a with supernatant of culture medium
containing VT2 thirteen times at 7-day intervals.
Prepar tio  ofcolostral whey without antibody
  Colostrum was treated to obtain colostral whey in the
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same manner as bovine colostral antibody against VT2.15
Thus, skim milk was obtained by centrifuging the
colostrum at 1,600 × g for 15 minutes in order to remove
fat. One liter of skim milk was then mixed with 100 mg of
rennet (ICN Biochemicals Inc., OH, USA) and incubated
overnight at 22eC. This skim milk was centrifuged at
2,200 × g for 20 minutes. Bovine colostral antibody was
obtained by filtering the supernatant using a membrane
filter (pore size: 22 pm).
Preparation of bovine plasma, bovine serum and rabbit
serum antibodies against VT2
  Bovine plasma antibody was obtained from 6-year-old
cows immunized with VT2. Bovine serum antibody was
obtained from 8-year-old cows.
  Japanese white rabbits were immunized with culture
medium containing VT2 suspended in Freund's complete
adjuvant (Difeo Laboratories, Detroit, USA), fbllowed by
the same culture medium 22 times. Rabbits were
sacrificed under pentobarbital anesthesia and blood was
collected. Antisera were obtained by centrifugation at
2,200 × g fbr20 minutes.
Measurement of neutralization titer
  Titers of bovine colostral antibody, bovine serum
antibody and rabbit serum antibody were tested by
neutralization test according to standard methods using
vero cells.12 Colostral antibody (40 ul) diluted from 2- to
2048-fOld was mixed with 40 ul of culture medium (MEM
culture medium; Nissui Pharmaceutical Co., Ltd., Tokyo)
containing VT2. This was incubated overnight at 37eC,
after which 100 pt1 of vero cells were added and cultured
for 2 days. Neutralization titer was measured based on the
number of dead vero cells.
Estimation of resistance to intestinal proteases in beagle
dogs
Comparison of resistance of bovine colostral antibody and
rabbit serum antibody to intestinal proteases in beagle
dogs
  Six beagle dogs were divided into two groups for
administratio  of bovine colostral antibody or rabbit
serum antibody. Each beagle dog was fasted for 18 hours
and was ally administered 50 ml of bovine colostral
antibody or rabbit serum antibody. Dogs were sacrificed at
1.5, 2, 3 or 4 hours after administration under anesthesia
by administrat on of pentobarbital and small intestinal
fluid including bovine colostral antibody or rabbit serum
a tibody was coll cted. Nothing was present in the small
intestine at 4 hours after administration and small
intestinal fluid could not be removed. Small intestinal
fluid wa  filtrated with a membrane filter (O.20 um) and
was stored under -80eC until measurement.
Measur ment of activities of bovine colostral and serum
antibodies by enzyme-linked immnosorbent assay
(ELISA)
  VT2 was adjusted with O.05 mol/L sodium
hydrogencarbonate buffer (pH 9.6), and was transferred to
immunoplates (Nunc, DK4000 Roskilde, Denmark). To
ll wells, 1% gelatin in O.05 mol/L sodium
hydrogencarbonate buffer (pH 9.6) was added at
200 #1/well in order to block non-binding sites. After
washing, small intestinal fluid including bovine colostral
antibody or rabbit serum antibody was added at
100 ul/well. Antibodies against to bovine immunoglobulin
(Mon san, Ud n, Netherlans) were added at 100 #Ilwell
 wells only conta ing wash samples from small
intestine fluid after administration of bovine colostral
antibody. Antibodies against rabbit immunoglobulin-
coup ed peroxidase (ICN Biomedicals, Costa Mesa,
Canada) were added to all wells at 100 "1/well. After
washing, 2,2-aminodi(3-ehtylbenzthiazoline sulphonic
acid (ABTS) (Invitrog n Corporation, CA, USA)) in
citrate buffer was added at 100 ul/well. Absorbance at 415
nm and 492 nm was then measured with an immunoplate
reader.
Comparison of resistance of each Ig class to intestinal
proteases in beagle dogs
  Fifty milliliters of bQvine colostral antibody or bovine
serum antibody was administered orally to fbur beagle
dogs in each group. Beagle dogs were then sacrificed at
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1.5, 2, 3 or 4 hours after administration under anesthesia
by administration of pentobarbital and intestinal fiuid was
removed. Intestinal fluid could not be collected at 4 hours
after administration. Small intestinal fluid was filtrated
with a membrane filter (O.20 ptm) and was stored under
-80"C until measurement.
Measurement of activity of each Ig class in small
intestinal fluid by ELISA
  Horseradish peroxidase-conjugated antibodies, antibody
against bovine IgA (a) (VMRD, Inc., WA, USA),
antibody against to bovine IgM (u) (VMRD, Inc.) and
antibody against IgG (" (VMRD, Inc), were used to
measured the activity of each Ig class･in small intestine by
ELISA. Horseradish peroxidase (Wako Pure Chemical
Industries, Ltd., Osaka, Japan)-conJ'ugated antibodies were
prepared using the method of Nakane and Kawaoi.i9
  VT2 was adjusted with O.05 mol/L sodium
hydrogencarbonate buffer (pH 9.6) and transferred to
immunoplates (Nunc). To all wells, 1% gelatin in O.05
mol/L sodium hydrogenca.rbonate buffer (pH 9.6) was
added at 200 pt11well to block non-binding sites. After
washing, small intestinal fluid collected from beagle dogs
was added at 100 pllwell. Horseradish peroxidase-coupled
antibody against bovine IgA (co (VMRD, Inc.), antibody
against bovine IgM (#) (VMRD, Inc.) or antibody against
IgG (" (MP Biomedical Inc.) were added at 100 ullwell
to wells. After washing, ABTS (Invitrogen Corporation)
in citrate buffer was added at 100 "11well. Absorbance at
415 nm and 492 nm was then measured with an
immunoplate reader.
Estimation of neutralization efficacy of bovine colostral
antibody against VT2 in beagle dogs inoculated with
E coli O157:H7
Comparison between bovine colostral antibody and
colostral whey
  Seven beagle dogs were divided into two groups. Four
beagle dogs were administered bovine colostral antibody
and three beagle dogs were 'administered bovine colostral
whey without antibody. Beagle dogs were administered
fradiomycin sulfate (FRM; Nippon Kayaku Co. Ltd.,
Tokyo, Japan) at 50 mg/kg for 3 days prior to inoculation
with E. coli O157:H7 in order to eliminate native
enterobacterial flora. Beagle dogs were fasted for 18 hours
prior to inoculation, and were then inoculated orally with
a feeding tube containing 5 ml of E. coli O157:H7
suspended in physiological saline. From the next day,
fosfomycin od um (FOM; Meiji Seika Kaisha, Ltd.,
Tokyo, Japan) at 50 mglkg was administered. Fecal
samples wer  collected daily after E. coli O157:H7
inoculation and fecal characteristics were noted. One
hundred milliliters of bovine colostral antibody or bovine
colostral wh y without antibody was administered orally
fo11owing conf rmat on of increased VT2 in feces. Titers
in feces a s own s geometric means. Unpaired
Studen 's t- est was us d to compare titers before and on
the day after adm nistration of bovine colostral antibody
or colostra  whey without antibody.
Comparison of bovine colostral antibody, serum antibody,
saline
  Nine bea le dogs wer  divided into three groups and
were used f r E. coli O157:H7 inoculation. Each group of
beagle dogs w  administered bovine colostral antibody,
plasma antibody or saline. The experimental procedures,
pretreatment of FRM, inoculation of E. coli O157:H7 and
administr ion of FOM, were similar to those in the
previous experiment. One hundred milliliters of bovine
colostral antibody, plasma antibody or saline was
administered orally fo11owing confirmation of increased
VT2 in feces. Titers in feces are shown as geometric
means. Unpaired Student's t-test was used to compare
titers before and the day after administration of bovine
colostral antibody, plasma antibody or saline.
                   Results
Neutralizatio  titer of bovine, plasma and serum antibody
  The neutralization titer of colostral antibody obtained
from 6-year- ld cows against VT2 was 1:32 by
neutralization test according to standard !nethods using
vero c lls. Bovine plasma antibody obtained from the
same co s was 1:8. Th  neutralization titer of colostral
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antibody obtained from 8-year-old cows against VT2 was
1:128. Bovine serum antibody obtained from the same
covvs was 1:32, The neutralization activities against VT2
were not confirmed in bovine colostral whey obtained
fiom non-immunized cows or in rabbit serum antibody.
Comparison of antibody activities between bovine
colostral antibody and rabbit serum antibody recovered
from small intestines of beagle dogs
  A comparison of the activity of bovine colostral
antibody and rabbit serum antibody in the small intestine
is shown in Figure 1. Activity of the bovine colostral
antibody did not change until 2 hours after administration.
At 3 hours after administration, activity had decreased by
20-fold. Activity of rabbit serum antibody decreased
immediately after administration, giving values of one-
tenth at both 1.5 and 2 hours after administration. The
activities of both bovine colostral antibody and rabbit
serum antibody were very low at 3 hours after
administration.
Comparison of antibody activity among each Ig class in
small intestinal fluid recovered from beagle dogs
  The activities of each antibody class in small intestinal
fluid of beagle dogs administered bovine colostral
antibody, bovine serum antibody are shown in Figures 2.
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IgG antibody ac ivity decreased by two-thirds, while IgM
antibody decreased by two-fifth at 2 hours after
administration of bovine colostral antibody; however, that
of S-IgA scarcely changed until 2 hours after
dm nistration. At 3 hours after administration, the
activity of secretory IgA (S-IgA) antibody decreased by
halL whil  that of IgG and IgM antibodies decreased to
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. Comparison of antibody activities between bovine
 colostral antibody and rabbit serum antibody recovered
 from sm ll intestine. F fty milliliters of bovine colostral
 antibody or rabbit serum antibody were administered to
 beagle dogs. Small intestinal fluid was colrected at 1.5, 2
 or 3 hours after admjnjstration. Antibody activities are
 given in terms of absorbance, as measured by ELISA.
 Time zero represents the antibody activity before
 administration.
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Comparison of antibody activities among each immunoglobulin recovered from the small intestine of beagle dogs
after administration of 50 ml of bovine colostral antibody or serum antibody. Small intestinai fluid was collected at
1.5, 2 or 3 hours after administration. Antibody actMties are given in terms of absorbance, as measured by
ELISA. Time zero represents the antibody activity before administration.
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                     Days after administrations
Changes in fecal VT2 levels after administration of bovine colostral antibody and bovine
colostral whey in beagle dogs inoculated with EScherichia coti O157:H7.Fosfomycin
(50 mg/kg) was administered next day of inoculation. Vertical arrow indicates the timing of
administration of 100 ml of bovine colostral antibody or bovine colostral whey. The
reciprocals of neutralizing test (NT) titers to VT2 are plotted on the ordlnate. Significant
difference obtained by unpaired Student's t-test is shown by * (p < O.05).
one-tenth and one-sixth, respectively. For bovine serum
antibodies, IgG and IgM activities decreased to one-fifth,
while IgA activity fe11 to after administration decreased to
half at 1.5 hours after administration.
Neutralization efficacy of bovine colostral antibody and
bovine colostral whey in beagle dogs inoculated with
E. coli O157:H7
  Changes in fecal VT2 levels after administration of
bovine colostral antibody or bovine colostral whey
without antibody in beagle dogs inoculated with E. coli
O157:H7 are shown in Figure 3.
  Bovine colostral antibody was administered to beagle
dogs when the amount of VT2 in feces increased 1:40.7,
and the amount decreased significantly to 1:12.6 by the
next day (p<O.05). The amount of VT2 in feces decreased
from 1:13.5 to 1:7.9 on the day after administration of
colostral whey without antibody. Furthermore, the amount
of VT2 in feces increased to 1:26.9 at 5 days after
moculation.
VT2 neutralizat on efficacy of bovine colostral and
plasma antibodies in beagle dogs inoculated with EL coli
O157:H7
  Changes in fecal VT2 levels after administration of
bovine colostral antibody, bovine plasma antibody or
saline in beagle dogs inoculated with EL coli O157:H7 are
shown in Figure 4. The amount of VT2 in feces decreased
significantly from 1:40.8 to 1:3.2 on the day after
administration of bovine colostral antibody (p<O.05), and
reached 1:1.3 at 7 days after inoculation. The amount of
VT2 in f ces also decreased on the day after
administration of bovine plasma antibody and saline (from
1:20.0 to 1:6.3, and from 1:20.0 to 1:10.0, respectively),
and gradually continued to decrease.
                  Discussion
  We previously obtained a bovine colostral antibody
against VT2 from cows immunized VT2 and confirmed its
neutralization efficacy against VT2 in mice administered
VT2 or inoculated with E. coli O157:H7 producing VT2.i4
If this bovine colostral antibody is to be administered
orally to patients infected E. coli O157:H7, it must be
resistant to protease degradation in the digestive tract. We
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                      Days after administration
Changes in fecal VT2 levels after administration of bovine colostral and plasma
antibodies, and saline in beagle dogs inoculated with Escherichia coti O157:H7.
Fosfomycin (50 mg/kg) was administered on the day after inoculation. Vertical arrow
indicates the timing of administration of 100 ml of bovine colostral antibody, bovine
p!asma antibody or saline. The reciprocals of neutralizing test (NT) titers to VT2 are
plotted on the ordinate. Significant difference obtained by unpaired Student's t-test is
shown by * (p < O.05).
thus investigated the resistance of this bovine colostral
antibody to intestinal proteases in beagle dogs, which was
presumed to secrete proteases more abundantly than mice
and be able to extrapolate to human.
  The beagle dogs inoculated live E. coli O157:H7 (1 ×
109 CFU/ml) without pre-treatment of antibiotics did not
show any symptoms as a diarrhea. For this reason, these
healthy dogs could not use in our study (data not shown).
The beagle dogs with normal enterobacterial flora may not
sensitive to E. coli O157:H7. E coli O157:H7 may remain
and/or grow in intestine of beagle dogs with pre-treated of
antibiotics. It was important to note that the experimental
beagle dogs in our study were pre-treated with antibiotics
to alter their indigenous enterobacterial flora. The beagle
dogs with pre-treated of FRM had slight or severe diarrhea
after inoculation E. coli O157:H7. These beagle dogs with
such pre-treatment could use in our study as an
experimental animal model for EL coli O157:H7 infection.
Furthermore, aminoglycoside antibiotics, such as FRM,
are poorly absorbed and largely pass through the
intestine.8･9 One day after administration was allowed for
excretion of FRM from the intestine prior to inoculation
with E: c l  O157:H7. Therefore, FRM did not influence
the elimination of E. coli O157:H7.
  The colostral tibody remained until 2 hours after
dministration, while the rabbit serum antibody was
significantly reduced at 1.5 hours after administration.
Furthermore, S-IgA class did not decrease as much and
IgG class mai ed at two-thirds until 2 hours after
administration. These results suggest that bovine colostral
antibody is m re resis ant to proteases when compared
with serum antibody in vivo,
 S-IgA is known o be more resistant to pepsin when
c mpared with serum IgA, as the presence of the secretory
compon nt (SC) helps resist proteolysis in vitro
experiments.i6･ 23･ 26'29 Less than 15% of S-IgA was
digested during in vit o experjment with papajn.28 In this
study, S-IgA antibody activity in the beagle dog intestine
r mained for 2 hours after administration of bovine
colostral ant body, and thus S-IgA showed similar
resistance as in vitro experiment.3, 25,26 On the other hand,
IgGl was digested completely in vitro experiment28, while
IgG ctivity in b agle dog intestine remained at
approximately tw -thirds of pretreatment values until 2
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hours after administration. These results suggested that
both S-IgA and IgG antibodies are thought to contribute
to the resistance of bovine colostral antibody to intestinal
proteases. Thus, the bovine colostral antibody against VT2
appears to be resistant to intestinal proteases, and is able
to maintain its neutralizing activity against VT2 in the
digestive tract.
  As the bovine colostral antibody was confirmed to be
resistant to intestinal proteases, the efficacy of bovine
antibody against VT2 in beagle dogs was then
investigated in additional studies.
  The amount of VT2 in feces decreased rapidly after
administration of bovine colostral antibody. The titer
decreased significantly the day after administration of
bovine colostral antibody. On the other hand, the amount
of VT2 in feces decreased gradually after administration
of colostral whey. Furthermore, the amount of VT2 in
feces increased at 2 days after administration of bovine
colostral whey without antibody. It has been reported that
E. coli O157:H7 does not flourish in the mouse intestine
due to commensal fiora.i8 This suggests that VT2 is not
neutralized by colostral whey without antibody and that
E. coli O157:H7 is able to survive and reproduce. The
bovine colostrum obtained from non-immunized cows
with antibodies against numerous pathogens showed
efficacy in mice infected with E. coli O157:H7.6･ i5
However, these results suggest that bovine colostral
antibody obtained from cows immunized with VT2 are
more effective at neutralizing VT2 than colostral whey.
  Next, we compared efficacy against VT2 among bovine
colostral antibody, plasma antibody and saline in beagle
dogs. The amount of VT2 in feces decreased significantly
the day after administration of bovine colostral antibody
than administration of plasma antibody or saline. This
result suggested that plasma antibody was digested by
proteases, similarly to rabbit serum, and decreased more
rapidly than bovine colostral antibodiy in the beagle dog
intestine. Therefore, the plasma antibody could not
neutralize VT2 effectively due to rapid degradation by
proteases. On the other hand, colostral antibody including
S-IgA and IgG was resistant to protease degradation and
showed sufficient neutralization efficacy against VT2 in
the intes ine.
  Bovine col strum containing antibodies has already
been applied again  human Rotavirus infection.2, 5･7
Howeyer, vine colostrum against human Rotavirus was
not investigated with regard to degradation in the small
intestine. Re istance to proteases in the small intestine and
efficacy against VT2 were thus investigated for the
present bovine colostral antibody. Based on the present
results, bovine colostrum obtained from cows immunized
with patho ens is us ful for neutralizing toxins and
pathogens. Little is available on comparisons of protease
activity in the small intestines of human and beagle dogs;
however, we used beagle dogs, as protease secretion is
thought to be comparable to that in.humans. Bovine
colostral antibody against VT2 including S-IgA and IgG
showed resistance to proteases in the small intestine of
beagle dogs, thus suggesting the possibility of resistance
to proteases in the human intestine. Treatment with both
FOM nd bovine colos ral antibody has also been
confirm d to improve the survival of mice infected by
E. coli O157:H7.i4 In the future, combination therapy with
antibiotics an  bovine colostral antibody against VT2 may
prevent serious omplications, such as HUS, in EHEC
infection.
  In summary, the efficacy of bovine colostral antibody
against VT2 was verified in digestive organs abundantly
secreting proteases. These results suggest that it is
possible for patients infected with E. coli O157:H7 to be
treated with oral bovine colostral antibody. Furthermore,
whe  administered w th antibiotics bovine colostral                                '
antibo y may effectively inhibit the activity of VT2
released from E. coli O157:H7.
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